KR20240146018A - Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 - Google Patents
Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 Download PDFInfo
- Publication number
- KR20240146018A KR20240146018A KR1020247028842A KR20247028842A KR20240146018A KR 20240146018 A KR20240146018 A KR 20240146018A KR 1020247028842 A KR1020247028842 A KR 1020247028842A KR 20247028842 A KR20247028842 A KR 20247028842A KR 20240146018 A KR20240146018 A KR 20240146018A
- Authority
- KR
- South Korea
- Prior art keywords
- combination
- arginine
- pharmaceutical combination
- sildenafil
- acetylcysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
| TW111104639 | 2022-02-09 | ||
| PCT/GB2023/050296 WO2023152500A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240146018A true KR20240146018A (ko) | 2024-10-07 |
Family
ID=85283927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247028842A Pending KR20240146018A (ko) | 2022-02-09 | 2023-02-09 | Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134892A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4475833A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025504219A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240146018A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116808224A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023219232A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI859506B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023152500A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI879058B (zh) * | 2023-08-31 | 2025-04-01 | 未來新藥股份有限公司 | Pde5抑制劑組合於促進神經突生長之新穎用途 |
| CN122055146A (zh) * | 2023-08-31 | 2026-05-15 | 未来新药股份有限公司 | Pde5抑制剂组合于促进神经突生长的新颖用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4699299A (en) | 1998-06-26 | 2000-01-17 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
| IL132460A0 (en) * | 1999-10-19 | 2001-03-19 | Laniado Shlomo | Sildenafil preparation |
-
2022
- 2022-02-09 TW TW111104639A patent/TWI859506B/zh active
-
2023
- 2023-02-09 WO PCT/GB2023/050296 patent/WO2023152500A1/en not_active Ceased
- 2023-02-09 CN CN202310100652.1A patent/CN116808224A/zh active Pending
- 2023-02-09 US US18/836,532 patent/US20250134892A1/en active Pending
- 2023-02-09 JP JP2024547249A patent/JP2025504219A/ja active Pending
- 2023-02-09 KR KR1020247028842A patent/KR20240146018A/ko active Pending
- 2023-02-09 AU AU2023219232A patent/AU2023219232A1/en active Pending
- 2023-02-09 EP EP23706081.9A patent/EP4475833A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116808224A (zh) | 2023-09-29 |
| US20250134892A1 (en) | 2025-05-01 |
| TW202332450A (zh) | 2023-08-16 |
| EP4475833A1 (en) | 2024-12-18 |
| WO2023152500A1 (en) | 2023-08-17 |
| AU2023219232A1 (en) | 2024-07-25 |
| JP2025504219A (ja) | 2025-02-06 |
| TWI859506B (zh) | 2024-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008240259C1 (en) | Tetrahydrobiopterin compositions and methods of measuring | |
| Ashraf et al. | Endothelium mediated vasorelaxant response of garlic in isolated rat aorta: role of nitric oxide | |
| WO2002003996A1 (en) | Use of dammarane-type tritepenoid saporins | |
| Yue et al. | Tanshinones inhibit NLRP3 inflammasome activation by alleviating mitochondrial damage to protect against septic and gouty inflammation | |
| US20250134892A1 (en) | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine | |
| JPH09278663A (ja) | カイガンショウからの抽出物(PycnogenolTM) の経口投与によるヒト血小板の反応性の調節方法 | |
| Fuentes et al. | Protection against indomethacin-induced loss of intestinal epithelial barrier function by a quercetin oxidation metabolite present in onion peel: In vitro and in vivo studies | |
| RU2014101261A (ru) | Системы, способы и составы для лечения рака | |
| KR101516677B1 (ko) | 지방성 간 질환의 치료용 의약 조성물 | |
| EP0003827A1 (en) | Antidepressant combination | |
| Gour et al. | Epicatechin exerts dual action to shield sickling and hydroxyurea-induced myelosuppression: Implication in sickle cell anemia management | |
| de Queiroz et al. | Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis | |
| JP5808772B2 (ja) | 肝細胞内のミトコンドリアの活性化方法 | |
| AU2006321942A1 (en) | Methods and compositions for the treatment of disease | |
| Dalal et al. | A systematic overview of bexagliflozin: A type 2 diabetic drug | |
| Chen et al. | Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection | |
| WO2025026900A1 (en) | Compounds for the treatment or prevention of gout | |
| US20120135078A1 (en) | Angina treatment | |
| KR20260021653A (ko) | IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄 | |
| US20130338203A1 (en) | TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR | |
| Bartko et al. | Recombinant human diamine oxidase activity is not inhibited by ethanol, acetaldehyde, disulfiram, diethyldithiocarbamate or cyanamide | |
| JP7837595B2 (ja) | 動脈硬化を含む老化関連血管疾患の治療又は予防用組成物としてのサイコサポニンc | |
| MX2014001679A (es) | Composicion farmaceutica que comprende un farmaco que contiene por lo menos una funcion de toxicoforo y n-acetil-l-cisteina. | |
| TWI451866B (zh) | 治療及預防患者因心肌缺血所引起的不適的醫藥組合物 | |
| Imperial | Effect of Aspalathus linearis supplementation, during anti-retroviral treatment, on the heart and aortas of male Wistar rats and the effects of drinking rooibos on the cardiovascular profile of patients on ART. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |